BR0211342A - Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cns - Google Patents
Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cnsInfo
- Publication number
- BR0211342A BR0211342A BR0211342-2A BR0211342A BR0211342A BR 0211342 A BR0211342 A BR 0211342A BR 0211342 A BR0211342 A BR 0211342A BR 0211342 A BR0211342 A BR 0211342A
- Authority
- BR
- Brazil
- Prior art keywords
- mutation
- virus
- mutant
- rabies
- viral
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title abstract 4
- 206010037742 Rabies Diseases 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 230000026731 phosphorylation Effects 0.000 title abstract 3
- 238000006366 phosphorylation reaction Methods 0.000 title abstract 3
- 102000011931 Nucleoproteins Human genes 0.000 title abstract 2
- 108010061100 Nucleoproteins Proteins 0.000 title abstract 2
- 241000711798 Rabies lyssavirus Species 0.000 title abstract 2
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 7
- 108010067390 Viral Proteins Proteins 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20141—Use of virus, viral particle or viral elements as a vector
- C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"VìRUS DE RAIVA ATENUADO COM MUTAçãO DE NUCLEOPROTEìNA NO SìTIO DE FOSFORILAçãO PARA VACINAçãO CONTRA RAIVA E TERAPIA DE GENE NA CNS". Um vírus mutante é provido o qual contem uma mutação em um sítio de fosforilação em uma ou mais das proteínas do vírus, cuja mutação faz com que o vírus seja atenuado, e por isso, uma composição de vacina aperfeiçoada pode ser produzida com o mesmo. A invenção também referese a composições de vacina que contêm os vírus mutantes, assim como a processos de indução de uma resposta imune, e de proteção de mamíferos de infecção por vírus da raiva. Também são incluídos na invenção processos de produção de vírus mutantes e proteínas virais, incluindo produção de vírus mutantes em uma célula hospedeira que produz ou mesmo super-produz uma contra-parte tipo selvagem da proteína viral mutante, que complementa as outras proteínas virais de modo que a produção da partícula viral mutante seja otimizada. A invenção também inclui aquelas células hospedeiras nas quais produção viral é otimizada, assim como composições de vacina incluindo as proteínas virais, tanto sozinhas como em combinação com os vírus intactos, e a processos de indução de uma resposta imune ou proteção de um mamífero contra infecção, usando as mesmas. Também são incluídos na invenção vetores apropriados para liberação de um gene para uma célula de um humano ou animal, assim como processo de liberação do mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33135401P | 2001-07-20 | 2001-07-20 | |
| PCT/US2002/023108 WO2003046506A2 (en) | 2001-07-20 | 2002-07-22 | Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0211342A true BR0211342A (pt) | 2005-05-03 |
Family
ID=23293602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0211342-2A BR0211342A (pt) | 2001-07-20 | 2002-07-22 | Vìrus de raiva atenuado com mutação de nucleoproteìna no sìtio de fosforilação para vacinação contra raiva e terapia de gene na cns |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US6706523B2 (pt) |
| EP (1) | EP1434862A4 (pt) |
| JP (1) | JP2005510249A (pt) |
| KR (1) | KR20040029377A (pt) |
| CN (1) | CN100346826C (pt) |
| AU (1) | AU2002365029A1 (pt) |
| BR (1) | BR0211342A (pt) |
| CA (1) | CA2454397A1 (pt) |
| CO (1) | CO5560623A2 (pt) |
| HR (1) | HRP20040078A2 (pt) |
| HU (1) | HUP0500722A2 (pt) |
| MX (1) | MXPA04000589A (pt) |
| NZ (1) | NZ531025A (pt) |
| PL (1) | PL371967A1 (pt) |
| WO (1) | WO2003046506A2 (pt) |
| YU (1) | YU6304A (pt) |
| ZA (1) | ZA200400340B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040029377A (ko) * | 2001-07-20 | 2004-04-06 | 더 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 | 공수병의 예방 접종 및 중추신경계 질환의 유전자 요법을위한 인산화 부위의 핵단백질 돌연변이를 갖는 약독화공수병 바이러스 |
| ES2535310T3 (es) * | 2004-04-09 | 2015-05-07 | Wyeth Llc | Atenuación sinérgica del virus de la estomatitis vesicular, vectores del mismo y composiciones inmunogénicas del mismo |
| WO2006017673A2 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
| CN100341571C (zh) * | 2005-09-16 | 2007-10-10 | 孙介光 | 一种治疗肿瘤的药物及该药物在制备治疗肿瘤药物中应用 |
| CN101287838B (zh) * | 2005-10-14 | 2016-03-30 | 美国政府健康及人类服务部，疾病控制和预防中心 | 狂犬病病毒组合物和方法 |
| US20100278864A1 (en) * | 2005-12-14 | 2010-11-04 | University Of Georgia Research Foundation, Inc. | Rabies Vaccine |
| WO2008054544A2 (en) * | 2006-05-22 | 2008-05-08 | Immune Disease Institute, Inc. | Method for delivery across the blood brain barrier |
| BRPI0919174B1 (pt) * | 2008-09-17 | 2020-11-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | vírus da raiva recombinante, composição imunogênica e seu uso |
| WO2012106490A1 (en) | 2011-02-03 | 2012-08-09 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Multivalent vaccines for rabies virus and filoviruses |
| CN102205119B (zh) * | 2011-04-12 | 2012-05-30 | 广州市华南农大生物药品有限公司 | 狂犬病灭活抗原及其制备方法 |
| KR101479668B1 (ko) * | 2012-07-31 | 2015-01-12 | 대한민국 | 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물 |
| CN106929482A (zh) * | 2015-12-31 | 2017-07-07 | 北京大学 | 定点突变的流感病毒、其活疫苗及其制备方法和应用 |
| KR20170002590U (ko) | 2016-01-08 | 2017-07-18 | 최문규 | 제조와 포장이 용이한 일회용 위생장갑 |
| US11041170B2 (en) | 2016-04-04 | 2021-06-22 | Thomas Jefferson University | Multivalent vaccines for rabies virus and coronaviruses |
| US11155885B2 (en) | 2016-05-20 | 2021-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Real-time reverse transcriptase-polymerase chain reaction assay with modified probe for the diagnosis of rabies viruses and other lyssaviruses |
| GB201706945D0 (en) * | 2017-05-02 | 2017-06-14 | Medical Res Council | Self-inactivating viral vector |
| EP4240412A4 (en) * | 2020-11-03 | 2025-09-03 | Univ Jefferson | VACCINE AGAINST GENE-REARRANGED LYSSAVIRUSES |
| WO2022178307A1 (en) * | 2021-02-19 | 2022-08-25 | Beam Therapeutics Inc. | Recombinant rabies viruses for gene therapy |
| CN114957408B (zh) * | 2021-02-24 | 2024-04-23 | 东莞博盛生物科技有限公司 | 一种狂犬病毒的preG改性蛋白及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| FR2693655B1 (fr) * | 1992-07-20 | 1994-10-14 | Virbac | Vaccin antirabique avirulent. |
| US5583735A (en) | 1994-01-18 | 1996-12-10 | Hollingsead International, Inc. | Aircraft video monitor deployment and retraction apparatus |
| DK0702085T4 (da) * | 1994-07-18 | 2010-04-06 | Conzelmann Karl Klaus Prof Dr | Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus |
| UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| US6719881B1 (en) | 1998-09-22 | 2004-04-13 | Charles R. Hunter | Acid colloid in a microparticle system used in papermaking |
| BR9915703B1 (pt) * | 1998-11-27 | 2012-09-04 | mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva. | |
| KR20040029377A (ko) * | 2001-07-20 | 2004-04-06 | 더 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 | 공수병의 예방 접종 및 중추신경계 질환의 유전자 요법을위한 인산화 부위의 핵단백질 돌연변이를 갖는 약독화공수병 바이러스 |
-
2002
- 2002-07-22 KR KR10-2004-7001006A patent/KR20040029377A/ko not_active Withdrawn
- 2002-07-22 YU YU6304A patent/YU6304A/sh unknown
- 2002-07-22 HR HR20040078A patent/HRP20040078A2/hr not_active Application Discontinuation
- 2002-07-22 PL PL02371967A patent/PL371967A1/xx not_active Application Discontinuation
- 2002-07-22 JP JP2003547898A patent/JP2005510249A/ja active Pending
- 2002-07-22 US US10/199,024 patent/US6706523B2/en not_active Expired - Fee Related
- 2002-07-22 MX MXPA04000589A patent/MXPA04000589A/es unknown
- 2002-07-22 BR BR0211342-2A patent/BR0211342A/pt not_active IP Right Cessation
- 2002-07-22 EP EP02803956A patent/EP1434862A4/en not_active Withdrawn
- 2002-07-22 NZ NZ531025A patent/NZ531025A/en unknown
- 2002-07-22 CN CNB02818436XA patent/CN100346826C/zh not_active Expired - Fee Related
- 2002-07-22 CA CA002454397A patent/CA2454397A1/en not_active Abandoned
- 2002-07-22 WO PCT/US2002/023108 patent/WO2003046506A2/en not_active Ceased
- 2002-07-22 HU HU0500722A patent/HUP0500722A2/hu unknown
- 2002-07-22 AU AU2002365029A patent/AU2002365029A1/en not_active Abandoned
-
2003
- 2003-12-09 US US10/730,029 patent/US7419816B2/en not_active Expired - Fee Related
-
2004
- 2004-01-16 ZA ZA200400340A patent/ZA200400340B/en unknown
- 2004-01-27 CO CO04005802A patent/CO5560623A2/es not_active Application Discontinuation
-
2007
- 2007-02-01 US US11/700,899 patent/US7544791B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20040078A2 (en) | 2004-08-31 |
| MXPA04000589A (es) | 2005-06-17 |
| AU2002365029A1 (en) | 2003-06-10 |
| US7419816B2 (en) | 2008-09-02 |
| PL371967A1 (en) | 2005-07-11 |
| WO2003046506A2 (en) | 2003-06-05 |
| EP1434862A4 (en) | 2005-04-06 |
| US6706523B2 (en) | 2004-03-16 |
| US20070178555A1 (en) | 2007-08-02 |
| NZ531025A (en) | 2005-08-26 |
| US20030099671A1 (en) | 2003-05-29 |
| US7544791B2 (en) | 2009-06-09 |
| ZA200400340B (en) | 2004-08-18 |
| YU6304A (sh) | 2006-08-17 |
| HUP0500722A2 (hu) | 2005-11-28 |
| CO5560623A2 (es) | 2005-09-30 |
| CA2454397A1 (en) | 2003-06-05 |
| US20040208900A1 (en) | 2004-10-21 |
| CN100346826C (zh) | 2007-11-07 |
| WO2003046506A3 (en) | 2004-04-22 |
| CN1635905A (zh) | 2005-07-06 |
| EP1434862A2 (en) | 2004-07-07 |
| JP2005510249A (ja) | 2005-04-21 |
| KR20040029377A (ko) | 2004-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU6304A (sh) | Atenuirani virus besnila sa nukleoproteinskom mutacijom u mestu za fosforilaciju za vakcinaciju protiv besnila i gensku terapiju u cns-u | |
| EA014062B1 (ru) | Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк | |
| CY1115749T1 (el) | Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια | |
| JP2007508848A (ja) | ソラレン不活化ｈｉｖに基づく免疫原性組成物及びワクチンの開発方法 | |
| Laver et al. | Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine | |
| ES2129386T1 (es) | Vacuna contra influenza. | |
| BR9510590A (pt) | Processo para produzir vacinas multivalentes de hemoglutinina de gripe. | |
| EE200300332A (et) | Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin | |
| US4725547A (en) | Method for purfication of rabic virus | |
| EP0173268B1 (en) | A method for the preparation of a herpes simplex virus subunit vaccine | |
| EA199800746A1 (ru) | Способ генерации противовирусного иммунного ответа у человека или животного | |
| Chen et al. | Glycan‐masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development | |
| Kallin et al. | Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells | |
| ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
| Rungsa et al. | Heterologous expression and mutagenesis of recombinant Vespa affinis hyaluronidase protein (rVesA2) | |
| CN1488641A (zh) | 抑制sars冠状病毒的多肽药物及其衍生物和其应用 | |
| MX2022016287A (es) | Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas. | |
| Liu et al. | Concurrent gene insertion, deletion, and inversion during the construction of a novel attenuated BoHV-1 using CRISPR/Cas9 genome editing | |
| Sugimoto et al. | Algal-lytic activities encoded by Chlorella virus CVK2 | |
| BR9912626A (pt) | Mutante do herpesvìrus equino, sequência de ácido nucleico, molécula de dna recombinante, célula hospedeira, vacina, e, processos para a preparação de um mutante de ehv e para atenuar geneticamente o ehv | |
| EA037291B8 (ru) | Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома sars-cov-2 (варианты) | |
| NO20006457L (no) | Vaksine-indusert hepatitt B viral stamme og anvendelser derav | |
| DE69633919D1 (de) | Mehrzweckvakzine gegen umhüllte viren | |
| RU2507257C1 (ru) | Рекомбинантная псевдоаденовирусная частица на основе генома аденовируса человека 5 серотипа для индукции специфического иммунитета к вирусу гриппа а субтипа н1n1 и способ ее использования в качестве компонента для создания вакцины | |
| MOROZ et al. | Enhancement of immunogenicity of snake venom neurotoxins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |